Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh ...

Bernstein analysts maintained their positive stance on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amidst a competitive ...

Also Read: Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall Omvoh works to reduce inflammation within ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...